The World Health Organization warned that artificial sweeteners, used to replace sugar in a vast range of products, do not help in losing weight and can have serious health effects.
According to the United Nations health agency, a systematic review of available evidence "suggests that use of non-sugar sweeteners (NSS) does not confer any long-term benefit in reducing body fat in adults or children.
In addition, results from the review suggest that the long-term use of NSS could increase the risk of type 2 diabetes, cardiovascular diseases, and mortality in adults.
The WHO's director for nutrition and food safety, Francesco Branca, stressed that replacing ordinary sugar with artificial sweeteners "does not help with weight control in the long term".
He added that NSS are not essential dietary factors and have no nutritional value.
The WHO said its new recommendation applied to everyone except individuals with pre-existing diabetes.
It includes all synthetic and naturally occurring or modified sweeteners not classified as sugars found in manufactured foods and beverages or sold on their own to be added to products by consumers.
Among the most widely used sweeteners are acesulfame K, aspartame, advantame, cyclamates, neotame, saccharin, sucralose, stevia, and stevia derivatives, it said.


U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Asian Markets Slip as AI Spending Fears Shake Tech, Wall Street Futures Rebound
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 



